2nd Circ. Asks How Expert Report Could Derail Pfizer Action
A Second Circuit panel wondered Tuesday how an extensively briefed securities fraud class action alleging Pfizer Inc. hid deadly risks associated with two painkillers could have been tossed on the eve...To view the full article, register now.
Already a subscriber? Click here to view full article